BeiGene Ltd.

BeiGene Ltd. is a biopharmaceutical company headquartered in Beijing, China, with a global presence. Founded in 2010, BeiGene focuses on the discovery, development, manufacturing, and commercialization of innovative medicines, with a particular emphasis on oncology and immunology.

The company is committed to advancing cutting-edge science to address unmet medical needs and improve the lives of patients worldwide. BeiGene has built a robust pipeline of potential therapies, including small molecules, monoclonal antibodies, and cell therapies, targeting a wide range of cancers and autoimmune diseases.

BeiGene has been actively involved in clinical trials and research collaborations, working with leading academic institutions and other pharmaceutical companies to accelerate the development of novel treatments. Their dedication to scientific excellence has earned them recognition in the pharmaceutical industry.

The company's first commercialized product was zanubrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, which received regulatory approval in several countries for the treatment of certain lymphomas. They have continued to expand their portfolio of approved products and investigational drugs, with a focus on precision medicine and personalized treatments.

Founded: 2010
Headquarters: Beijing, China
Website: https://www.beigene.com/